Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 103 clinical trials
None
The Benefit of Surgery in Stage IV of Breast Cancer

Treatment of Metastatic Breast Cancer is not usually considered curative. Recent retrospective studies have demonstrated that resection of the breast tumor in patients with primary metastatic breast cancer is associated with a significant improvement of the prognosis. In all these aforementioned studies, the decision to perform surgery could have been …

  • 0 views
  • 27 Jan, 2021
  • 1 location
None
Partial Irradiation and Sequential vs. Concurrent Chemo Early Breast Cancer

In a small study at Johns Hopkins, women were treated with partial breast irradiation and chemotherapy given at the same time. We are now testing in a bigger study whether giving partial breast irradiation and chemotherapy at the same time (our new method) has the same side effects and outcomes …

paclitaxel
doxorubicin
breast adenocarcinoma
endocrine therapy
trastuzumab
  • 12 views
  • 23 Sep, 2021
  • 11 locations
None
TEAM-Trial: Targeting Epigenetic Therapy Resistance in AML With Bortezomib

The long-term outcome of patients with acute myeloid leukemia (AML) remains poor, with less than 30% of patients achieving long lasting remission or cure. This poor outcome is largely due to refractoriness to induction chemotherapy as well as relapses during and after completion of intensive induction and consolidation therapy. In …

neoadjuvant therapy
cell transplantation
gemtuzumab
acute promyelocytic leukemia
remission
  • 0 views
  • 24 Jan, 2021
  • 1 location
None
Efficacy and Safety of Sintilimab and Apatinib Combined Chemotherapy in Breast Cancer

The efficacy and safety of immunotherapy and antiangiotherapy in combination with chemotherapy in neoadjuvant therapy for triple-negative breast cancer (TNBC) were determined by the addition of sintilimab and apatinib to neoadjuvant chemotherapy To clarify the breast-conserving rate, toxicity, difference in pathologic complete response (pCR) rate of patients with PD-L1 (+) …

EGFR
estrogen receptor
HER2
paclitaxel
mastectomy
  • 0 views
  • 19 May, 2021
  • 1 location
None
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines

This randomized pilot phase I trial studies the side effects of donor bone marrow derived mesenchymal stem cells in controlling heart failure in patients with cardiomyopathy caused by anthracyclines. Donor bone marrow derived mesenchymal stem cells may help to control symptoms of heart failure and improve heart function.

walk test
heart failure
trastuzumab
medical therapy
cardiomyopathy
  • 0 views
  • 14 Oct, 2021
  • 1 location
None
Recommendations for the Treatment of Children With Acute Lymphoblastic Leukemia in the GFAOP

The LALGFA2019 Recommendations redefine the standard risk criteria and propose to introduce anthracycline induction in so-called high-risk forms (LAL line T and LAL line B with leukocytosis

  • 0 views
  • 28 Nov, 2021
  • 2 locations
None
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

This clinical trial studies the effects of dexrazoxane hydrochloride on biomarkers associated with cardiomyopathy and heart failure after cancer treatment. Studying samples of blood in the laboratory from patients receiving dexrazoxane hydrochloride may help doctors learn more about the effects of dexrazoxane hydrochloride on cells. It may also help doctors …

chemotherapy regimen
dexrazoxane hydrochloride
cell transplantation
second cancer
anthraquinone
  • 52 views
  • 05 Aug, 2021
  • 42 locations
None
Evaluation of Measurable Residual Disease in Patients With Acute Myeloid Leukemia as Surrogate Endpoint for Survival

Objectives To demonstrate that measurable residual disease assessed by multiparameter flow cytometry during intensive treatment is a surrogate for overall survival and thus an early read-out for drug efficacy Study design Surrogate endpoint trial to establish that measurable residual disease assessed by multiparameter flow cytometry during intensive treatment is a …

  • 0 views
  • 29 Jan, 2021
  • 1 location
None
Risk-stratified Therapy Based on Molecular Cytogenetic Aberration and Treatment Response in AML

Risk-stratified therapy based on molecular and cytogenetic for acute myeloid leukemia (AML) is well accepted and benefits patients' survival. However, neither every patient with low risk factors obtains better survival, nor all high risk patients experience worse outcome. Lots of data have shown that the early treatment response presenting as …

leukemia
chromosomal abnormalities
myeloid leukemia
  • 1 views
  • 23 Jan, 2021
  • 1 location
None
Evaluation of Myocardial Injury After Anthracycline Chemotherapy in Osteosarcoma Patients Using CMR

well as LVEF and extracellular volume(ECV) to evaluate the respective changes before and after anthracycline chemotherapy.

anthracyclines
cancer chemotherapy
chemotherapy regimen
myocardial injury
MRI
  • 5 views
  • 25 Jan, 2021
  • 1 location